Compare ACNT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | UNCY |
|---|---|---|
| Founded | 1945 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 145.3M |
| IPO Year | 1995 | 2021 |
| Metric | ACNT | UNCY |
|---|---|---|
| Price | $15.26 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 100.6K | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.62 | $3.72 |
| 52 Week High | $17.92 | $8.74 |
| Indicator | ACNT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 38.30 |
| Support Level | $13.35 | $4.18 |
| Resistance Level | $15.46 | $5.59 |
| Average True Range (ATR) | 0.56 | 0.73 |
| MACD | 0.09 | -0.17 |
| Stochastic Oscillator | 71.67 | 29.48 |
Ascent Industries Co is a specialty chemicals company focused on the development, production, and distribution of tailored, performance-driven chemical solutions. Its customers are spread across energy, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), agriculture, water treatment, pulp and paper, construction, automotive, and other industrial markets. The company's core product portfolio includes surfactants, defoamers, lubricating agents, flame retardants, and specialty intermediates, offered in both petroleum-based and bio-based formulations. Geographically, it generates maximum revenue from the United States, followed by Mexico, Canada, Honduras, Colombia, the Netherlands, Costa Rica, Japan, and other markets.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.